AzTrials
AzTrials

Cerebral Palsy (CP)NCT06486597

Whole Body Metabolism in Children With Cerebral Palsy With Low Skeletal Muscle Mass

A study testing Meal in people with Cerebral Palsy (CP), run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

At the center of pediatrics in Copenhagen the investigators experience that the children with CP with low skeletal muscle mass have more complications and admission after for example surgery is prolonged due to these complications. Read more about this study

Who is it for?
Ages 2 to 18 yearsHealthy volunteers can take part
Conditions the study is for
Cerebral Palsy (CP)
What is being tested?
Meal
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteDenmark
Study dates
1 Aug 2023to 31 Jul 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • -Children with cerebral palsy with low skeletal muscle mass
  • o Being wheelchair dependent GMFCS IV-V
  • Healthy controls: Children admitted to the EMU because of either
  • Classification of epilepsy or to rule out differential diagnoses of epilepsy
  • Nocturnal EEG changes
  • Age:
  • o 2-18 years
  • Signed informed consent to participation in the trial.

Who cannot join

  • Inability to understand the purpose of the trial or cooperate in the conduction of the experiments. For the children this will concern of course the parents or the guardians of the child.
  • Competing conditions at risk of compromising the results of the study.
  • In healthy children, concerns that participation in the trial may affect the diagnostic quality of the EMU investigation
  • Participation in other trials that may interfere with the results.
  • Intake of medications that may interfere with the results, evaluated by investigator.
  • Pregnancy or breastfeeding.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Denmark1 site, 1 recruiting
  • Department of Pediatrics and Adolescent Medicine and Copenhagen Neuromuscular Center, Rigshospitalet

    Copenhagen, Copenhagen Ø, 2100

    Mette Cathrine Ørngreen, MD, DMSc, 35455935, mette.cathrine.oerngreen.01@regionh.dk

    Mette Cathrine Ørngreen, MD, DMSc

    Recruiting

Other trials in Denmark

About this study

At the center of pediatrics in Copenhagen the investigators experience that the children with CP with low skeletal muscle mass have more complications and admission after for example surgery is prolonged due to these complications. In order to prevent malnutrition and energy insufficiency as well as obesity and cardiometabolic disorders in adulthood, and with the aim of defining biomarkers for energy needs, the investigators wish to determine energy and protein needs in children with CP.

The investigators wish to investigate the whole-body metabolism in children with cerebral palsy (CP) and compare the results with results from healthy children. The investigators aim to include 10 children (aged 2-18 years) with CP with low skeletal muscle mass and 10 healthy controls (aged 2-18 years). By using stable isotope technique the investigators will investigate systemic fat, glucose and protein metabolism together with liver protein degradation and glucose production. Furthermore, by using DXA scan the investigators will describe the quality and distribution of skeletal muscle. Lastly, the investigators will determine the skeletal muscle signal pathway and metabolism in skeletal muscle via the Bergström biopsy technique in vastus lateralis.

Read the detailed description

Trial design and time frame:

A prospective, non-randomized, cross-sectional study.

There will be two different groups included:

  • Children with cerebral palsy with low skeletal muscle mass
  • Healthy controls: Children admitted to the hospital at the Epilepsy monitor unit (EMU for conditions not affecting metabolic function)

The trial will be conducted over a total of five days and takes place at the Copenhagen Neuromuscular Centre, Department of Neurology or Department of Pediatrics and Adolescent Medicine, Rigshospitalet

Study Day 1: The patient will be DXA-scanned or fat mass will be measured by a fat caliper, and the patient will complete quality of life questionnaire and pain scores.

Study Day 2 (Study type A): The stable isotope infusion will take place. The subjects will arrive around 08.00, at Copenhagen Neuromuscular Centre (CNMC), Rigshospitalet or Department of Pediatrics and Adolescents medicine, Rigshospitalet. Otherwise, the study will take place when the child is admitted for change of baclofen pump or minor surgery, where they typically will be hospitalized for 1-3 days at Rigshospitalet or Skejby hospital at the Department of Pediatrics and Adolescents or the Orthopedic Departments.

On arrival, EMLA (local anesthetics cream) will be applied on the skin of the children to minimize any discomfort that may occur during IV-insertion. Two peripheral venous catheters are inserted, one in the medial cubital vein for infusion of stable isotopes, and one in a dorsal vein of the hand for blood sampling. Most of the children already have a permanent catheter, and in this case the permanent catheter will be used for infusion of stable isotopes.

Background samples will be collected before the start of tracer infusion. After 1 hour and 45 minutes of basal tracer infusion, basal blood samples are drawn (time -15 and -30) for the determination of basal steady state tracer enrichments and hormone concentrations. At time= 0, a liquid mixed meal is provided. Blood samples are drawn regularly for 6 hours and more frequently the first hour after the test meal ingestion (at 0, 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300 and 360 minutes). If the child becomes upset or the investigators for other reasons want to stop earlier than 6 hours, the already obtained blood and urine samples will be analyzed and included in the results.

Study days 3, 4, and 5 (Study type B and C):

These study days are optional to the families and the investigator. For some families one study day is what they can fit into their calendar, and the investigators want to respect that, for those who accept to continue the study for more than one day, the following days are included.

The doubly labeled water technique measures energy consumption over a prolonged period, in our study for 1 week. A drink with doubly labeled water will be ingested, and energy expenditure is measured by urine and blood sampling. This method is repeated at 3 hours and 4 hours after the drink intake and again at day 3 and day 7. Furthermore, a drink with 13C will be ingested, and breath tests collected in vacutainers with straws will be collected for analysis of energy expenditure. Measuring energy expenditure with these two less non-invasive methods and comparing results with the detailed meal test, will pave the way for developing simple diagnostic markers for metabolism in the children.

The tracers: In this study, the investigators will intravenously infuse small amounts of metabolites labelled with stable isotopes in primed continuous intravenous infusions of: D8-Phenylalanine, D2-Tyrosine, 13C18-Oleate acid, D2-Glucose, D5-Glycerol. This method is well-established at both CIMT and CNMC and has been used investigating several of patients categories before: Neonates (ongoing study), gastric sleeve, elderly and neuromuscular patients.

The tracers are prepared from the hospital pharmacy. All tracers are purchased from Cambridge Isotope Laboratories, Andover, MA, USA suitable for human use. Stable isotopes are non-radioactive and naturally occurring in food (e.g. in corn).

Food intervention: At time= 0 (120 minutes after infusion), a liquid mixed meal adjusted by weight is given. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Intrinsically labeled caseinate was produced via an infusion of [D5]-phenylalanine and [D3]leucine into a lactating cow to obtain enriched milk Foulumn, Arhus University, from which the caseinate fraction was isolated at Arla Foods according to Good Manufacturing Practice (GMP) and safety checked an store under appropriate regulatory conditions until use (Nørre Vium, Denmark) following a previously described procedure.

Analyses of blood samples:The samples will be collected in syringes containing 10μL EDTA/mL to prevent coagulation. The blood is immediately centrifuged at 4oC to separate plasma from red blood cells. The samples will be frozen in coded tubes and stored at -80C until analysis.

Routine blood samples: Will be analysed immediately at the Department of Clinical Biochemistry, Rigshospitalet:

  • Blood samples include: Insulin, HbA1C, Cholesterol, HDL, LDL, triglycerides

Glucose and lactate: will be analyzed (ABL 700) immediately as the blood is drawn.

Specific blood samples:

Free fatty acids: will be analyzed using fluorometry. Hormones (catecholamines, insulin, incretins and glucagon): will be analyzed using RIA and Elisa Methods respectively. Stable isotope enrichments in blood: will be analyzed using Liquid chromatography-tandem mass-spectrometry (LC-MS/MS) and gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS) (Thermo Scientific, Palo Alto, CA, USA and Bremen, Germany). Calculations: Whole body metabolite quantitative kinetics will be calculated using Steele's equation for non-steady state adapted for analysis of stable isotopes under the post-absorptive conditions.

Being tested
Meal
Medical subject headings
Cerebral Palsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MealDietary supplement

    Liquid meal

Study groups in NCT06486597
Study groupRoleWhat they receive
Meal intervention with stable isotopesExperimentalA liquid mixed meal are gived adjusted by weight. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Blood samples are drawn frequently to measure fat, glucose and protein metabolism.
Receives: Dietary Supplement: Meal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Protein breakdown

    Phenylalanine Rate of appearance micro mol/kgFFM/min in a fasted and fed state

    Measured: 10 hours

Secondary outcomes (11)
  1. Muscle biopsy

    Muscle morphology

    Measured: 10 hours

  2. Life quality score

    Life quality score by using Pediatric Quality of Life Inventory (PedsQL) (0-100), high score indicates worse qualiity of life.

    Measured: 10 hpurs

  3. Quality of Skeletal Muscle

    Dual-energy X-ray absorptiometry (DEXA) scan

    Measured: 10 hours

  4. Metabolities

    Concentration of plasma amino acids (mmol/L), concentration of glucose (mmol/L), concentration of palmitate (micromol/L), concentration of free fatty acids (mmol/L) and levels of HbA1c (mmol/mol)

    Measured: 10 hours

  5. Hormones

    Concentration of Insulin (pmol/L), concentration of catecholamines (nmol/l) , glucagon (pmol/L), gut hormones and incretins (GLP-1 (pmol/L) and GIP, (pmol/L))

    Measured: 10 hours

  6. Energy utilization

    Energy expenditure assessed by doubly labeled water method and 13C breath test to test that these methods are valuable and can be used in the future as less expensive and invasive methods to measure energy utilization.

    Measured: 10 hours

  7. Muscle biopsy

    muscle fiber type

    Measured: 10 hours

  8. muscle biopsy

    size

    Measured: 10 hours

  9. Muscle biopsy

    Protein markers: MuRF1, MAFbx, FoxO (ng/mg total protein)

    Measured: 10 hours

  10. Muscle biopsy

    muscle generating markers: Myo D, Myogenin, IGF1 (ng/mg total protein )

    Measured: 10 hours

  11. Muscle biopsy

    Muscle growth regulating protein (myostatin)

    Measured: 10 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jul 2024
  2. Study start1 Aug 2023
  3. Primary completion31 Jul 2028 (estimated)
  4. Study completion31 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06486597
Sponsor's protocol ID
22-B01-1066
Status last verified
Feb 2025
First submitted
17 May 2024
Last updated
26 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Meal in people with Cerebral Palsy (CP), run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Protein breakdown (time frame: 10 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in